Coya TherapeuticsCOYA
COYA
About: Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Employees: 8
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
37% more funds holding
Funds holding: 19 [Q3] → 26 (+7) [Q4]
19% more capital invested
Capital invested by funds: $21.4M [Q3] → $25.5M (+$4.08M) [Q4]
4.81% more ownership
Funds ownership: 21.78% [Q3] → 26.59% (+4.81%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
166%
upside
Avg. target
$16
204%
upside
High target
$18
242%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target | 242%upside $18 | Buy Maintained | 27 Mar 2025 |
Chardan Capital Keay Nakae 13% 1-year accuracy 9 / 72 met price target | 166%upside $14 | Buy Maintained | 20 Mar 2025 |
Financial journalist opinion
Based on 4 articles about COYA published over the past 30 days
Neutral
Business Wire
2 weeks ago
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer's disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna. The presentation, titled, “A Phase II.
Positive
Zacks Investment Research
3 weeks ago
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock
Coya Therapeutics, Inc. (COYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet
The consensus price target hints at a 149.6% upside potential for Coya Therapeutics, Inc. (COYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Business Wire
3 weeks ago
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today provides a status update of its investigational regulatory T cell-derived exosome (Treg exosomes) platform intended for the treatment of systemic and neurodegenerative diseases driven by chronic inflammation. Sustained inflammatory responses driven by dysfunctional immune regulation is.
Neutral
Business Wire
1 month ago
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Ph.
Neutral
Business Wire
1 month ago
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast “Is Alzheimer's next for GLP-1s and Combos?” on February 27, 2025 to discuss the potential treatment of Al.
Positive
Seeking Alpha
2 months ago
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD
Coya Therapeutics, Inc. has Treg therapies for neurodegenerative and autoimmune diseases, targeting ALS, FTD, AD, and PD. However, their lead candidate is now clearly COYA 302. This drug basically combines low-dose IL-2 and CTLA4-Ig, and it's now progressing toward Phase 2 trials for ALS and FTD. COYA 301 was intended for AD, but its mixed Phase 2 results may be why COYA is now pivoting toward COYA 302.
Positive
Seeking Alpha
2 months ago
Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch
Potential initiation of phase 2b study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in 2025 barring successful IND clearance by the FDA. Biomarker data from proof-of-concept study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in Q2 of 2025. The global Amyotrophic Lateral Sclerosis market is expected to reach $1.33 billion by 2033.
Positive
Benzinga
2 months ago
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
On Thursday, Coya Therapeutics, Inc. COYA announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer's disease (AD).
Neutral
Business Wire
2 months ago
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announced encouraging blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer's disease (AD). Statistically significant reduced levels of proinflammatory markers were observed in patients.
Charts implemented using Lightweight Charts™